MURRIETA, CA--(Marketwire - May 22, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today released the May 2008 edition of its investor newsletter, which reviews the announcement of a letter of intent to acquire a rapid diagnostic test for the medical market and the initiation of the first stages of a pre-clinical trials validation study on Zonda Incorporated’s rapid point of care test for chlamydia.
